Dynavax to Present Data on SD-101 in Combination with KEYTRUDA(R) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
The details of the poster presentation are as follows:
Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naïve & experienced metastatic melanoma patients.
Track: Melanoma/Skin Cancers
Location: Hall A; Board #158
For information about SD-101 trials that are currently recruiting patients, please visit www.clinicaltrials.gov.
This press release contains "forward-looking" statements, including expectations for the conduct of clinical trials of SD-101. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether we can timely provide adequate clinical supplies; initiation, enrollment and completion of clinical trials of SD-101; the results of clinical trials and the impact of those results on the initiation or continuation of subsequent trials and issues arising in the regulatory process; the ability to successfully develop and commercialize SD-101; and whether or not
KEYTRUDA® is a registered trademark of
News Provided by Acquire Media